These convergent changes suggest that Retatrutides effects on cognition may involve mechanisms extending beyond peripheral metabolic regulation, potentially including modulation of inflammatory and neurotrophic-related pathways
This will be hypothesis-generating rather than a regulatory endpoint trial, but the results will inform the design of a potential dedicated Phase 3 kidney outcomes study
Safety : Semaglutide is FDA-approved, ensuring federal standards for safety and effectiveness have been met
This process keeps food in the digestive system for longer making people feel fuller for longer, thus reducing appetite and inducing weight loss
These may include: Nausea (affecting approximately 20-40% of patients, depending on the specific medication) [17] Mild abdominal discomfort or bloating Changes in bowel habits , including constipation or occasionally diarrhoea Reduced appetite , which whilst therapeutic, can feel unusual initially These effects are generally mild to moderate and tend to improve as the body adjusts to the medication, typically within 24 weeks
Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
